Table 1.
Data for 10 151 patients with complete demographic and medication data identified as having hypertension and type 2 diabetes by eGFR categories from the Joslin Diabetes Center
| Characteristics | eGFR < 30 (n = 565) | eGFR 30–60 (n = 2230) | eGFR 60–90 (n = 3924) | eGFR > 90 (n = 3432) | P-value for trend |
|---|---|---|---|---|---|
| Age, years, mean (95% CI) | 71.0 (60.0–79.0) | 73.0 (66.0–81.0) | 67.0 (59.0–74.0) | 57.0 (49.0–64.0) | <0.001 |
| Sex, male, n (%) | 293 (51.9) | 1116 (50.0) | 2090 (53.3) | 2124 (61.9) | <0.001 |
| HT, inches, mean (95% CI) | 66.0 (63.0–69.0) | 66.0 (63.0–69.0) | 67.0 (63.8–70.0) | 68.0 (65.0–70.5) | <0.001 |
| WT, lbs, mean (95% CI) | 186.0 (154.8–220.6) | 190.0 (162.0–224.0) | 192.0 (163.6–224.0) | 198.0 (170.0–231.0) | <0.001 |
| BMI, mean (95% CI) | 29.9 (25.3–35.0) | 30.4 (26.6–35.3) | 30.1 (26.3–34.5) | 30.2 (26.6–34.9) | 0.52 |
| eGFR, mg/dL, mean (95% CI) | 21.4 (13.9–25.7) | 48.1 (41.2–54.6) | 76.3 (68.6–81.9) | 105.6 (96.7–120.0) | <0.001 |
| Medication category, n (%) | |||||
| No meds | 38 (6.7) | 125 (5.6) | 179 (4.6) | 128 (3.7) | <0.001 |
| 1 Med | 442 (78.2) | 1228 (55.1) | 1850 (47.1) | 1715 (50.0) | |
| 2 Meds | 66 (11.7) | 612 (27.4) | 1250 (31.9) | 975 (28.4) | |
| 3 Meds | 16 (2.8) | 226 (10.1) | 538 (13.7) | 523 (15.2) | |
| >3 Meds | 3 (0.5) | 39 (1.7) | 107 (2.7) | 91 (2.7) | |
| Statin, n (%) | 421 (74.5) | 1810 (81.2) | 3029 (77.2) | 2446 (71.3) | <0.001 |
| Nonstatin, n (%) | 68 (12.0) | 279 (12.5) | 365 (9.3) | 256 (7.5) | <0.001 |
| Aspirin, n (%) | 358 (63.4) | 1524 (68.3) | 2462 (62.7) | 1741 (50.7) | <0.001 |
| Insulin, n(%) | 462 (81.8) | 1563 (70.1) | 2469 (62.9) | 2297 (66.9) | <0.001 |
| Insulin only, n (%) | 396 (70.1) | 955 (42.8) | 1267 (32.3) | 1218 (35.5) | <0.001 |
| Other than insulin, n (%) | 65 (11.5) | 547 (24.5) | 1283 (32.7) | 1015 (29.6) | <0.001 |
| Insulin and other, n (%) | 66 (11.7) | 608 (27.3) | 1202 (30.6) | 1079 (31.4) | <0.001 |
| Metformin, n (%) | 8 (1.4) | 642 (28.8) | 2128 (54.2) | 1891 (55.1) | <0.001 |
| Sulfonylurea, n (%) | 98 (17.3) | 625 (28.0) | 1033 (26.3) | 820 (23.9) | 0.62 |
| Thiazolidinedione, n (%) | 11 (1.9) | 83 (3.7) | 101 (2.6) | 73 (2.1) | 0.018 |
| DPP4 inhibitor, n (%) | 38 (6.7) | 257 (11.5) | 382 (9.7) | 235 (6.8) | <0.001 |
| Acarbose, n (%) | 2 (0.4) | 11 (0.5) | 16 (0.4) | 27 (0.8) | 0.08 |
| Nateglinide, n (%) | 1 (0.2) | 3 (0.1) | 7 (0.2) | 3 (0.1) | 0.53 |
| Repaglinde, n (%) | 9 (1.6) | 34 (1.5) | 59 (1.5) | 31 (0.9) | 0.03 |
| Pramlintide, n (%) | 3 (0.5) | 15 (0.7) | 36 (0.9) | 54 (1.6) | 0.004 |
| GLP-1 inhibitor, n (%) | 2 (0.4) | 54 (2.4) | 169 (4.3) | 170 (5.0) | <0.001 |
Sulfonylurea drugs: glipizide, glyburide, glimeperide, tolbutamide.
Thiazolidinediones: rosiglitazone, pioglitazone.
DPP4 inhibitors: sitagliptan, linagliptan, saxagliptan.
GLP-1 inhibitors: liraglutide, exenatide.